High-risk cytogenetics and extramedullary disease may be associated with worse survival outcomes of CAR T-cell therapy in relapsed or refractory multiple myeloma, a meta-analysis suggests.
The FDA has accepted for priority review the biologics license application for elranatamab to be used as a treatment for patients with relapsed or refractory multiple myeloma.
Phase 3 trial results support the use of carfilzomib, lenalidomide, and dexamethasone as maintenance after autologous stem cell transplant in patients with multiple myeloma.
Adding daratumumab to lenalidomide and dexamethasone extends overall survival in relapsed/refractory multiple myeloma, according to final results from the POLLUX trial.
The MonumenTAL-1, MajesTEC-2, OPTIMUM/MUKnine, and GMMG-CONCEPT trials have shown promising results for patients with newly diagnosed or relapsed/refractory multiple myeloma.
Isatuximab plus carfilzomib, lenalidomide, and dexamethasone can produce deep responses in patients with high-risk, newly diagnosed multiple myeloma, a phase 2 trial suggests.